文献速递免疫规划卫生政策与健康促进

日本未接种HPV疫苗青少年中类疫苗不良反应症状的患病率:VENUS研究数据库描述性研究

Prevalence of HPV vaccine-associated symptoms in unvaccinated Japanese adolescents: A descriptive study from the VENUS study database.
PubMed 文献 · Vaccine · 2025-11-29

该研究利用日本四个市町村的医保理赔与免疫登记链接数据库,纳入2017年4月至2022年3月期间10-19岁未接种HPV疫苗者,计算27种类似HPV疫苗接种后不良事件的多样化症状(DS)患病率。结果显示DS总体患病率为0.15%,女性略高于男性,最常见为皮肤问题、睡眠障碍、头痛和月经不规律,各市町村及COVID-19期间无实质变化。结论提示未接种HPV疫苗的青少年中也可客观观察到DS。

要点

  • 未接种HPV疫苗的10-19岁青少年中DS总体患病率为0.15%。
  • 女性DS患病率略高于男性,最常见症状因年龄和性别而异。
  • 各市町村及COVID-19疫情期间DS患病率无实质变化。

核心结论

  • 即使在未接种HPV疫苗的日本青少年中,也可客观观察到类似疫苗接种后不良事件的多样化症状。

研究设计与样本

  • 基于人群的描述性研究,利用VENUS研究数据库链接四个日本市町村的国民健康保险理赔与免疫登记数据。
  • 纳入2017年4月至2022年3月有理赔记录的10-19岁未接种HPV疫苗者。
  • DS定义为文献中已识别的27种症状的ICD-10编码,持续超过3个月视为发病,并由儿科医生共识排除有明确基础疾病者。
  • 按财政年度、年龄组和性别计算DS患病率。

主要发现

  • DS共发生1891例,总体患病率为0.15%。
  • 女性DS患病率略高于男性。
  • 最常见的症状为皮肤问题(男性10-14岁,0.83%)、睡眠障碍(女性15-19岁,0.44%)、头痛(女性10-14岁,0.40%)和月经不规律(女性15-19岁,0.38%)。
  • 各市町村之间及COVID-19疫情期间DS患病率无实质变化。

临床怎么用

  • 结果为HPV疫苗安全性沟通提供客观背景数据,有助于解释未接种者中也可出现的类似症状。
  • 可支持日本提高HPV疫苗覆盖率的公共卫生沟通策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Japan, the proactive recommendation of human papillomavirus (HPV) vaccination was suspended in 2013 and resumed in 2022, with the HPV vaccination coverage rate slow to recover following this 9-year pause. The purpose of this study was to calculate the prevalence of diverse symptoms (DS) similar to adverse events following HPV vaccination in unvaccinated individuals. METHODS: This population-based descriptive study utilized data from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study database, which links National Health Insurance claims and immunization registries in four Japanese municipalities. Unvaccinated persons aged 10-19 years with claims from April 2017 to March 2022 were included. DS were defined using ICD-10 codes for 27 symptoms previously identified in the literature, with persistence exceeding 3 months considered indicative of onset. Cases with identifiable underlying disease were excluded by consensus review of pediatricians. Prevalence of DS was calculated by the fiscal year, age group, and sex. RESULTS: DS occurred in 1891 cases. The overall prevalence of DS was 0.15 %, and prevalence was slightly higher in females than males. The most common symptoms were skin problems (in males aged 10-14 years, 0.83 %), sleep disorders (females aged 15-19 years, 0.44 %), headache (females aged 10-14 years, 0.40 %), and menstrual irregularities (females aged 15-19 years, 0.38 %). No substantial variations in prevalence were observed across municipalities or during the COVID-19 pandemic. CONCLUSIONS: Our results provide objective evidence of DS even in Japanese adolescents who have not received the HPV vaccine. These results could help support improving HPV vaccine coverage in Japanese adolescents.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kawazoe Y, Katsuta T, Tanaka T, et al. Prevalence of HPV vaccine-associated symptoms in unvaccinated Japanese adolescents: A descriptive study from the VENUS study database. Vaccine. 2025. PMID: 41319438. doi:10.1016/j.vaccine.2025.128020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。